Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avastin Passes Tox Test In Colon Cancer

This article was originally published in The Pink Sheet Daily

Executive Summary

Drug and control arms in C-08 study of Genentech drug turn out the same.

You may also be interested in...



Avastin Breast Cancer Approval In Spotlight With AVADO

CHICAGO - First placebo-controlled, double-blinded evidence for bevacizumab in first-line metastatic breast cancer presented at ASCO.

Genentech Expects Avastin Colon Cancer Data Ahead Of Schedule In 2009

Revised timeline for the C-08 trial does not change Genentech’s assessment of probability of success.

“Creative” FDA Clears Avastin For First-Line Breast Cancer

Accelerated approval wants more clinical proof.

Topics

UsernamePublicRestriction

Register

ID1132327

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel